Skip to content

Pain control in burn patients

Effects of lidocaine intravenous infusion with placebo on background pain control on burned patients that admitted to emergency room in Velaiat hospital in Rasht

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201406116186N5
Enrollment
66
Registered
2014-08-30
Start date
2014-09-10
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain control in burn patients. Burns of multiple regions, at least one burn of third degree mentioned

Interventions

Intervention 1: Intervention 2) Lidocaine 1.5 ml/kg bolus and infusion is 1.5 ml/kg/h. Intervention 2: Intervention 2) Normal saline 0.15 ml/kg bolus then infusion is 1.5 mg/kg/h.

Sponsors

Vice chancellor for research of Guilan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age between 18-60 years American society Anesthesiologists class I, II total body surface area burns 20% to 40%, second and third-degree burn in upper and lower limbs and trunk

Exclusion criteria

Exclusion criteria: Sensitivity to the local anesthetics and opiates pregnancy a history of neuropathic and chronic pain addiction hepato-renal diseases cardiac disease especially arrhythmia

Design outcomes

Primary

MeasureTime frame
Pain. Timepoint: evaluated at baseline and after 1, 2, 4, 8, 12, 16, 20, 24 hours after intervention. Method of measurement: 11-point Numerical Rating Scale (NRS).;Sedation level. Timepoint: evaluated at baseline and after 1, 2, 4, 8, 12, 16, 20, 24 hours after intervention. Method of measurement: Ramsay Score.

Secondary

MeasureTime frame
Complications. Timepoint: evaluated at baseline and after1, 2, 4, 8, 12, 16, 20, 24 hours after intervention. Method of measurement: observation of any complications such as convulsion, nausea, vomiting, pruritus, urine retention, drowsiness, and respiratory depression.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBahram Naderi Nabi

Guilan University of Medical Sciences

naderi_bahram@yahoo.com+98 13 1321 0434

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026